Patient perspectives on choosing buprenorphine over methadone in an urban, equal-access system

American Journal on Addictions

Volumn 22, Issue 3, 2013, Pages 285-291

  Gryczynski, Jan ^a   Jaffe, Jerome H ^a,b   Schwartz, Robert P ^a   Dušek, Kristi A ^a   Gugsa, Nishan ^a   Monroe, Cristin L ^a   O'Grady, Kevin E ^c   Olsen, Yngvild K ^d   Mitchell, Shannon Gwin ^a  

^a FRIENDS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d Institutes for Behavior Resources   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; COCAINE; DIAMORPHINE; METHADONE; OPIATE AGONIST;

ADULT; AFRICAN AMERICAN; ARTICLE; BLEEDING; BODY POSTURE; CALCIUM DEPLETION; DEEP SEDATION; DIABETES MELLITUS; DRUG DEPENDENCE TREATMENT; FEMALE; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE SYSTEM; HELP SEEKING BEHAVIOR; HUMAN; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; OPEN ENDED QUESTIONNAIRE; OUTPATIENT; PATIENT DECISION MAKING; PATIENT PREFERENCE; PRODUCTIVITY; SKIN DISCOLORATION; SLEEP WALKING; STOMACH DISEASE; SWELLING; URBAN AREA; WEIGHT GAIN; WITHDRAWAL SYNDROME;

EID: 85027954806     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1111/j.1521-0391.2012.12004.x     Document Type: Article

References (35)

1. Amato L, Davoli M, Perucci CA, et al. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: Available evidence to inform clinical practice and research. J Subst Abuse Treat. 2005; 28: 321-329. (Pubitemid 40733141)
2. NIH Consensus Development Panel on Effective Medical Treatment of Opiate Addiction (NIH). Effective medical treatment of opiate addiction. JAMA. 1998; 280: 1936-1943.
3. Jaffe JH, O'Keeffe C., From morphine clinics to buprenorphine: Regulating opioid agonist treatment of addiction in the United States. Drug Alcohol Depend. 2003; 70 (2 Suppl.): S3-S11. (Pubitemid 36556056)
4. Weber EM., Failure of physicians to prescribe pharmacotherapies for addiction: Regulatory restrictions and physician resistance. J Health Care Law Policy. 2010; 13: 49-76.
5. Stanton A., The SAMHSA Evaluation of the Impact of the DATA Waiver Program. Summary Report. Rockville, MD: WESTAT; 2006.
6. Knudsen HK, Ducharme LJ, Roman PM., Early adoption of buprenorphine in substance abuse treatment centers: Data from the private and public sectors. J Subst Abuse Treat. 2006; 30: 363-373. (Pubitemid 43729149)
7. Agency for Healthcare Research and Quality. Community partnerships and provider training increase service capacity and access to long-term treatment for individuals with heroin addiction. AHRQ Healthcare Innovations Exchange. Available at: http://www.innovations.ahrq.gov/content.aspx?id=1827. Accessed November 28, 2011.
8. Schwartz RP, Highfield DA, Jaffe JH, et al. A randomized controlled trial of interim methadone maintenance. Arch Gen Psychiatry. 2006; 63: 102-109. (Pubitemid 43037474)
9. Gryczynski J, Schwartz R, O'Grady K, Jaffe J., Treatment entry among individuals on a waiting list for methadone maintenance. Am J Drug Alcohol Abuse. 2009; 35: 290-294.
10. Mitchell SG, Kelly SM, Gryczynski J, et al. African American patients seeking treatment in the public sector: Characteristics of buprenorphine vs. methadone patients. Drug Alcohol Depend. 2012; 122: 55-60.
11. Peterson JA, Schwartz RP, Mitchell SG, et al. Why don't out-of-treatment individuals enter methadone treatment programs ? Int J Drug Policy. 2010; 21: 36-42.
12. Schwartz RP, Kelly SM, O'Grady KE, et al. Attitudes toward buprenorphine and methadone among opioid-dependent individuals. Am J Addict. 2008; 17: 396-401.
13. Gryczynski J, Schwartz RP, Salkever DS, et al. Patterns in admission delays to outpatient methadone treatment in the United States. J Subst Abuse Treat. 2011; 41: 431-439.
14. Mitchell SG, Kelly SM, Brown BS, et al. Incarceration and opioid withdrawal: The experiences of methadone patients and out-of-treatment heroin users. J Psychoactive Drugs. 2009; 41: 145-152.
15. Mitchell SG, Kelly SM, Brown BS, et al. Uses of diverted methadone and buprenorphine by opioid-addicted individuals in Baltimore, Maryland. Am J Addict. 2009; 18: 346-355.
16. Mitchell SG, Morioka R, Reisinger HS, et al. Redefining retention: Recovery from the patient's perspective. J Psychoactive Drugs. 2011; 43: 99-107.
17. Reisinger HS, Schwartz RP, Mitchell SG, et al. Premature discharge from methadone treatment: Patient perspectives. J Psychoactive Drugs. 2009; 41: 285-296.
18. Schwartz RP, Kelly SM, O'Grady KE, et al. In-treatment vs. out-of-treatment opioid dependent adults: Drug use and criminal history. Am J Drug Alcohol Abuse. 2008; 34: 17-28.
19. Schwartz RP, Kelly SM, O'Grady KE, et al. Antecedents and correlates of methadone treatment entry: A comparison of out-of-treatment and in-treatment cohort. Drug Alcohol Depend. 2011; 115: 23-29.
20. McLellan AT, Kushner H, Metzger D, et al. The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat. 1992; 9: 199-213.
21. Brown BS, Benn GJ, Jansen DR., Methadone maintenance: Some client opinions. Am J Psychiatry. 1975; 132: 623-626.
22. Brown BS, Jansen DR, Benn GJ., Changes in attitude toward methadone. Arch Gen Psychiatry. 1975; 32: 214-218.
23. Miles MB, Huberman AM., Qualitative Data Analysis, 2nd edn. Thousand Oaks, CA: Sage Publications; 1994.
24. Joseph H, Stancliff S, Langrod J., Methadone maintenance treatment (MMT): A review of historical and clinical issues. Mt Sinai J Med. 2000; 67: 347-364.
25. Hunt DE, Lipton DS, Goldsmith DS, et al. 'It takes your heart': The image of methadone maintenance in the addict world and its effect on recruitment into treatment. Int J Addict. 1985-1986; 20: 1751-1771. (Pubitemid 16104757)
26. Goldsmith DS, Hunt DE, Lipton DS, et al. Methadone folklore: Beliefs about side effects and their impact on treatment. Hum Organ. 1984; 43: 330-340.
27. Fischer B, Chin AT, Kuo I, et al. Canadian illicit opiate users' views on methadone and other opiate prescription treatment: An exploratory qualitative study. Subst Use Misuse. 2002; 37: 495-522. (Pubitemid 34591773)
28. Rosenblum A, Magura S, Joseph H., Ambivalence toward methadone treatment among intravenous drug users. J Psychoactive Drugs. 1991; 23: 21-27.
29. Stancliff S, Myers JE, Steiner S, et al. Beliefs about methadone in an inner-city methadone clinic. J Urban Health. 2002; 79: 571-578. (Pubitemid 36076530)
30. Murphy S, Irwin J., " Living with the dirty secret": Problems of disclosure for methadone maintenance clients. J Psychoactive Drugs. 1992; 24: 257-264.
31. Korthuis PT, Gregg J, Rogers WE, et al. Patients' reasons for choosing office-based buprenorphine: Preference for patient-centered care. J Addict Med. 2010; 4: 204-210.
32. Pinto H, Maskrey V, Swift L, et al. The SUMMIT trial: A field comparison of buprenorphine versus methadone treatment. J Subst Abuse Treat. 2010; 39: 340-352.
33. Johanson CE, Arfken CL, di Menza S, Schuster CR., Diversion and abuse of buprenorphine: Findings from national surveys of treatment patients and physicians. Drug Alcohol Depend. 2012; 120: 190-195.
34. Monte AA, Mandell T, Wilford BB, et al. Diversion of buprenorphine/ naloxone coformulated tablets in a region with high prescribing prevalence. J Addict Dis. 2009; 28: 226-231.
35. Schuman-Olivier Z, Albanese M, Nelson SE, et al. Self-treatment: Illicit buprenorphine use by opioid-dependent treatment seekers. J Subst Abuse Treat. 2010; 39: 41-50.